Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medpace HoldingsFRA:01P +0.49%95 Cyclically Adjusted PS Ratio is 12.99 as of Jul. 25, 2026, which is 19% above its 10-year median of 10.94. GuruFocus rates FRA:01P with a GF Score™ of 95/100 and a GF Value™ of €463.14 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 136 Medical Diagnostics & Research companies, Medpace Holdings ranks worse than 87.5% on this metric.
The historical rank and industry rank for Medpace Holdings's Cyclically Adjusted PS Ratio or its related term are showing as below:
FRA:01P'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 8.2 Med: 10.94 Max: 15.39
Current: 12.84
During the past years, Medpace Holdings's highest Cyclically Adjusted PS Ratio was 15.39. The lowest was 8.20. And the median was 10.94.
FRA:01P's Cyclically Adjusted PS Ratio is ranked worse than 87.5% of 136
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.89
vs FRA:01P: 12.84
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Medpace Holdings's adjusted revenue per share data for the three months ended in Jun. 2026 was €21.502. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €40.83 for the trailing ten years ended in Jun. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Medpace Holdings (FRA:01P) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Medpace Holdings Cyclically Adjusted PS Ratio Related Terms
Medpace Holdings Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Medpace Holdings's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medpace Holdings Cyclically Adjusted PS Ratio Chart
FRA:01P vs ICLR, RVTY, CRL: Cyclically Adjusted PS Ratio Comparison
For the Diagnostics & Research subindustry, Medpace Holdings's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medpace Holdings Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Medpace Holdings's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Medpace Holdings's Cyclically Adjusted PS Ratio falls into.
Medpace Holdings Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Medpace Holdings's Cyclically Adjusted PS Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 12.99 mean?
Medpace Holdings (FRA:01P) has a Cyclically Adjusted PS Ratio of 12.99 as of Jul. 25, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Medpace Holdings and its competitors. This is 19% above median its historical median of 10.94. Over the past decade, Medpace Holdings' Cyclically Adjusted PS Ratio has ranged from 8.20 to 15.39. According to the industry distribution chart, Medpace Holdings ranks #119 out of 136 companies in the Medical Diagnostics & Research industry, placing it in the top 87.5%.
Is Medpace Holdings' Cyclically Adjusted PS Ratio too high?
Medpace Holdings' current Cyclically Adjusted PS Ratio of 12.99 is 19% above median its 10-year median of 10.94. Over the past 10 years, this metric has ranged from a low of 8.20 to a high of 15.39. The Medical Diagnostics & Research industry median Cyclically Adjusted PS Ratio is 1.89. Medpace Holdings' value of 12.99 is 587.3% above this industry median. Based on the distribution chart, Medpace Holdings ranks #119 out of 136 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Medpace Holdings has a GF Score™ of 95/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medpace Holdings' Cyclically Adjusted PS Ratio compare to ICLR and RVTY?
According to the Medical Diagnostics & Research industry distribution chart, Medpace Holdings ranks #119 out of 136 companies for Cyclically Adjusted PS Ratio. This places Medpace Holdings in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 1.89. Medpace Holdings' value of 12.99 is 587.3% above this benchmark. Historically, Medpace Holdings' own Cyclically Adjusted PS Ratio has ranged from 8.20 to 15.39 over the past decade. While the company's 10-year median is 10.94 vs. the industry median of 1.89, Medpace Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Medical Diagnostics & Research company?
The median Cyclically Adjusted PS Ratio among Medical Diagnostics & Research companies is 1.89, based on 136 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medpace Holdings's current Cyclically Adjusted PS Ratio of 12.99 is 587.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Medpace Holdings and its competitors. For the Medical Diagnostics & Research industry, the median Cyclically Adjusted PS Ratio is 1.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medpace Holdings's current Cyclically Adjusted PS Ratio is 12.99, which is 19% above median its own 10-year median of 10.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medpace Holdings stock overvalued right now?
Based on GuruFocus' analysis, Medpace Holdings (FRA:01P) is currently considered Modestly Overvalued. The stock's GF Value™ is €463.14, compared to a current price of €530.40 — trading 14.5% above its estimated fair value. The current Cyclically Adjusted PS Ratio is 12.99, which is 19% above median its 10-year median of 10.94 and 587.3% above the Medical Diagnostics & Research industry median of 1.89. Medpace Holdings' overall GF Score™ is 95/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Medpace Holdings (FRA:01P), the current Cyclically Adjusted PS Ratio is 12.99 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medpace Holdings (FRA:01P) Overvalued in 2026?
Based on GuruFocus' analysis, Medpace Holdings stock appears to be overvalued.
The current stock price of €530.40 is trading 14.5% above its estimated GF Value™ of €463.14.
GuruFocus considers Medpace Holdings to be Modestly Overvalued.
Key valuation signals for FRA:01P:
Cyclically Adjusted PS Ratio: 12.99 (19% above median its 10-year median of 10.94)
GF Value™: €463.14 vs. price of €530.40 (14.5% above fair value)
Industry Position: 587.3% above the Medical Diagnostics & Research median (#119 of 136)
No single metric tells the full story. See the FRA:01P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
95GF Score
Get the complete analysis for FRA:01P
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:01P has been successfully added to your 
